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The MHC of the mouse (H-2 complex) exerts a marked influence on resistance 
against murine viral lymphomagenesis (1-7). Resistance genes to various murine 
leukemia  virus  (MuLV)  1 isolates  have  been  mapped  (1-6)  to  several  regions 
within the H-2 complex, i.e. the K, I-A, I-E, S, and/or D regions. In one study 
(8), complementation with respect to resistance between the I-A and I-E regions 
was observed. 
The  H-2 influence on susceptibility to MuLV-induced lymphomas is usually 
compatible with H-2-controlled immunological resistance mechanism(s) directed 
against MuLV or MuLV cell surface antigens (3, 9-16). H-2-controlled immune 
mechanisms were shown to operate at the level of antiviral  antibodies (1 1,  14- 
16), virus-specific proliferating T  cells (12), virus-specific cytotoxic T  cells (10), 
or I region-linked inhibition of the outgrowth of preleukemic cells (13). 
A  second mechanism  by which the MHC influences lymphomagenesis in the 
mouse, besides immune response regulation, is variation in the level of expression 
of MHC molecules on tumor cells. So far this issue has only been investigated 
for class  I  MHC  molecules.  H-2-1inked  resistance  to  radiation  leukemia  virus 
infection has been associated (9,  10) with an increased and selective expression 
of certain class I  MHC antigens.  Transfection of the AKR K36 cell line, which 
lacks K k cell surface expression (17,  18), with a transcriptionally active K k gene, 
makes this  cell  line  much  less transplantable  in  syngeneic  recipient  mice (18), 
possibly due to enhanced susceptibility to Kk-restricted MuLV-specific cytotoxic 
T  cells (17,  18). Some Moloney MuLV-induced T  cell tumors and SJL/J B cell 
tumors have lost expression of certain class I MHC molecules (19, 20). 
Other  experimental  models  also  indicate  a  role  for  aberrant  class  I  MHC 
expression in tumorigenesis. Imbalance in the expression of class I H-2 molecules 
influences the metastatic properties of lung carcinoma (21), sarcoma (22-25) and 
B16  melanoma  cells  (26)  in  mice.  The  oncogenic  potential  of  adenovirus- 
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1  Abbreviation used in this paper: MuLV, murine leukemia virus. 
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transformed rat cells is  correlated  with  the  adenovirus E1A  product(s),  which 
influence(s) class  I  MHC expression (27,  28).  Introduction and expression of a 
transfected  class  I  MHC  gene  was  sufficient  to  abrogate  the  oncogenicity of 
highly tumorigenic adenovirus  12-transformed mouse cells (29). 
Previously,  we  described  the  induction  and  phenotypic  characteristics  of a 
large  number  of lymphomas  of H-2-congenic  C57BL  and  BALB/c  mice  that 
arose spontaneously (6), were induced by milk-transmitted ecotropic MuLV (6), 
or by neonatal  inoculation of cloned MuLV (7,  30).  Analysis of class  II  MHC 
antigen expression on a series of B 10.A(H-2  a) lymphomas indicates that (a) most 
primary B cell lymphomas express high levels of both I-A and I-E antigens at the 
cell surface, (b) some B cell lymphomas have an I-A-, I-E  + phenotype, (c) the loss 
of cell surface I-A expression can be the result of either a diminished A~ or Al3 
mRNA expression, and (d) one of the I-A-,  I-E  + B  cell tumors contains a  (11; 
17) translocation with a  breakpoint on chromosome  17 within or very close to 
the  H-2  complex.  To  our  knowledge  this  is  the  first  detailed  description  of 
imbalanced class II MHC expression in an animal tumor model. 
Materials and Methods 
Tumor  Induction.  The  development  of  the  C57BL/10ScSn  [B10(H-2b)]  and 
B10.ASgSn [B10.A(H-2a)]  sublines, virus-negative or with milk-transmitted B-ecotropic 
MuLV,  was  described in  detail  before (6).  The induction  of lymphomas by neonatal 
inoculation with  cloned MuLV  isolates has been  described (7,  30).  B10.A  mice were 
purchased from Olac Ltd., Bicester, United Kingdom. For evaluation of tumor incidence, 
animals were observed three times a  week for signs  of tumor development or general 
il[ness. Moribund mice were killed for autopsy and viable cell suspensions from lymphomas 
were frozen with a programmed cooling device and cryopreserved in liquid nitrogen in 
10%  DMSO as described (6).  In addition,  tumor tissues  were directly frozen in liquid 
nitrogen for DNA and RNA analyses. 
Tumor Cell Characterization.  Haematologic neoplasias were classified morphologically 
according to the  Pattengale-Taylor classification (31).  The characterization of the cell 
surface markers expressed by the lymphoma cells was performed by flow cytofluorometry 
on a Coulter Epics-C.  Data were collected from 5,000 viable cells by using logarithmic 
amplification of  signals from the photomultiplier tubes and plotted on a linear fluorescence 
scale. 
Antibodies.  The rat mAb directed against Thy-1  (59AD2.2) (32),  B220 (RA3-2C2) 
(33),  Lyt-1 (53-7.3) (32),  Lyt-2 (53-6.7) (32), Y200 (30G12) (32), and mac-1  (M1/70.15) 
(34)  were  used  at  1:1  dilutions  of tissue  culture  supernatant  containing  mAb.  The 
characteristics of the mAb directed against the I-A, I-E, and K  k antigens used in this study 
are summarized in Table I. The haplotype specificity of anti-MHC mAb was confirmed 
by their reaction with spleen cells  of a  panel of recombinant C57BL mice. Anti-MHC 
mAb were used at 1  : 100 dilutions of ascites containing mAb. As second antibodies in the 
flow cytofluorometry experiments, the following fluorescein-labeled antisera were used: 
goat  anti-mouse  Ig  (1:20;  Central  Laboratory of the  Netherlands  Red  Cross  Blood 
Transfusion Service) and rabbit anti-rat Ig (1:50; Cappel Laboratories, Cochranville, PA). 
DNA  Analysis.  Isolation  of cellular  DNA  was  performed as  described  (40).  DNA 
samples (I 5 #g) were digested under conditions recommended by the suppliers (Boehrin- 
ger-Mannheim Diagnostics, Inc., Mannheim, Federal Republic of Germany). Gel electro- 
phoresis,  transfer  to  nitrocellulose filter and  hybridization to  32P-labeled  probes  was 
carried out as described (41). As molecular weight markers, Hind III-digested phage 
DNA was used.  Finally, filters were washed in 0.1 ×  SSC plus 0.1% SDS for 15 min at 
60°C (class I I MHC-specific probes) or 65 °C (AKV [AKR leukemia virus]-LTR probe), 
dried, and autoradiographed with Kodak X-Omat R film and intensifying screens. 
RNA Analysis.  For RNA isolation, frozen tissues  were homogenized with a polytron ZIJLSTRA ET  AL.  1215 
TABLE  I 
Characteristics of Mouse Anti-MHC mAb 
Molecule  Hybrid cell line  Ig class  detected  Haplotype reactivity  Reference 
B17-263R1  IgM  I-A  b, d,j, p, g  35 
B17-123R2  IgM  I-A  b, d,j, p, g, r, (s)*  35 
17/227R7  IgG2a  I-A  b, d, j, k, (u)  35 
25-9-17S  IgG2a  I-A  b, d, (p), (q)  36 
34-5-3S  IgG2a  I-A  b, d, (p), (q)  37 
28-16-8S  IgG2a  I-A  b, d  36 
K25-8-7  IgG2a  I-A  b, f, k, r, s, q  G. H~immerling, 
unpublished  data 
11-5.2*  lgG2b  I-A  k  38 
11-3.25'  IgG2b  I-A  f, k, r, s  38 
13/18  IgG2a  I-E  d,j, k, p, r, u, v  35 
14-4-4S  IgG2a  I-E  d, k, p, r  39 
11-4.1*  IgG2a  H-2K  k, r, p, q  38 
* Weak crossreactivity. 
* Obtained from Becton Dickinson and Co. (Mechelen, Belgium). 
(30 s, full speed) at 0°C in 3 M  LiCI, 6 M  urea, and maintained overnight at 4°C. After 
centrifugation at  15,000 g for 1 h, the pellet was dissolved in  10 mM Tris-HCl, pH 7.5, 
and  1 mM EDTA. Subsequently the RNA was deproteinized by phenol and subsequent 
chloroform/isoamyl alcohol (24:1) extraction, and precipitated with ethanol. For dot-blot 
analysis, RNA was dissolved in  10 mM Tris-HCl (pH 7.5),  1 mM EDTA, and applied to 
nitrocellulose filters as described (42). Northern blot analysis of RNA with formaldehyde- 
treated  1.0% agarose gels was performed as described (27). Hybridization to s~pdabeled 
probes was carried  out as described (41).  Finally, filters were washed in 0.1x  SSC plus 
0.1% SDS at 60 °C for 15 min, dried, and autoradiographed with Kodak X-Omat R film 
and intensifying screens.  To remove radioactive label, filters were washed at 68°C for 2 
h  in  H20/formaldehyde  1:1  (vol/vol) and  preexposed  to x-ray film  to ensure  that  no 
residual label was left. 
Hybridization Probes.  The hybridization probe specific for the U3-LTR of AKV-MuLV 
(AKV-LTR) has been described in detail previously (43).  The following class II MHC- 
specific hybridization probes were used: Aa, an Eco RI fragment,  containing an almost 
full length Aa  a cDNA inserted into the Eco RI site of pBR322 (44); A/~, pclA/3-1, a 464 
bp 3' cDNA probe encompassing the transmembrane,  intracytoplasmic, and 3' untrans- 
lated region of A[3  d, inserted  in the  Pst  1 site of pBR322 (45); Ea, an ~700  bp cDNA 
clone of Ea  d inserted into the Pst  1 site of pBR322 (R. N. Germain, unpublished data); 
E/3, an ~500 bp cDNA clone containing the/32, transmembrane, and cytoplasmic region 
ofE/~  a subcloned into pUC8 (R. N. Germain, unpublished data). 
Cytogenetic Studies.  Tumor-bearing mice were injected 20 min before section with  10 
#g demecolcine (Sigma Chemical Co., St. Louis, MO) dissolved in HBSS. Tumor-affected 
organs  were  removed,  mechanically  dissociated  through  a  fine  metal  gauze,  and  the 
resulting cells were centrifuged for 10 min at 1,200 rpm. The cell pellet was resuspended 
in  0.075  M  KCI at  37°C and incubated  at 370C for 25 min.  Before centrifugation (10 
min at  1,200 rpm) a few drops of freshly prepared fixative (methanol/glacial acetic acid, 
3:1) was added and  mixed  thoroughly.  After centrifugation,  the  cell  pellet  was gently 
resuspended  in  fresh  fixative,  and  any  remaining  pieces  of tissue  or cell clumps  were 
discarded.  The cell suspension  was allowed  to stand at  room temperature  for 25  min, 
centrifuged, and resuspended  in fresh fixative.  This last step was repeated until a  clear 
cell suspension was obtained.  Air-dried preparations were made on alcohol-cleaned glass 
slides. 
Chromosome preparations  were stored for -14 d  at room temperature  before being 
stained by a G-banding technique based on that of Herbst et al. (46). Basically, slides were 1216  IMBALANCED  I-A/E  EXPRESSION ON  MURINE  B CELL TUMORS 
TAnLE  II 
Characteristics of Two Primary B IO.A B Cell Lymphomas with Strongly Reduced I-A Cell Surface 
Expression 
Mouse lymphocyte differentia-  Class lI MHC expres- 
tion markers  sion  Age 
PrimarYtumor  Strain  Sex  (mo)  Inducing agent  Histology* 
T200  Thy  Mac-1  B220  slg  Con-  trol  I*A  I-E 
1189  B10.A  ~  19  Milk-transmit-  +*  -  -  +  +  700  81  90  lmmunoblastic 
ted MuLV  521  60  188 
1464  BI0.A  9  29  Spontaneous  +  -  -  +  +  20  50  86  Lymphoblastic 
40  48  192 
12424  BI0,A  d  13.5  Milk-transmit-  +  -  +  +  39  91  86  Follicle center cell, 
ted MuLV  60  188  187  large cell type 
* Classification according to Pattengale and Taylor (31). 
* +, strong expression; _+, weak expression; -, no expression. 
| Percentage of cells above channel 30. 
w  Mean intensity of fluorescence (channel number) of cells above channel 30. 
i Representative primary B10.A B cell with a strong I-A/E expression. 
incubated in  2×  SSC  at  60°C  for 60-120  min,  rinsed in  distilled water, and then  in 
buffer, pH 6.8 (Gurr). A short trypsin treatment of ~ 10 s followed (0.17% Difco trypsin 
1:250 in buffer, pH 6.8 [Gurr]) at 4°C, with rinsing in distilled water and buffer, pit 6.8 
(Gurr). Slides were then stained in a  5% Giemsa (BDH Chemicals, Ltd., Poole, United 
Kingdom) solution in buffer, pH 6.8 (Gurr), rinsed in distilled water, dried, and mounted 
in fluoromount (BDH, Chemicals, Ltd.). Suitable metaphases were photographed using 
Kodak technical Pan film 2415, and karyotyped according to the standard nomenclature 
(47). 
Results 
Cell-surface  I-AlE  Expression  of Primary  BIO.A  B  cell  Lymphomas.  The  cell 
surface  I-A/E  expression  of 24  primary  B10.A  (I-A  k,  I-E  k)  B  cell  tumors  was 
determined  by  flow  cytofluorometry with  a  panel  of nine  I-A-  and  two  I-E- 
reactive  mAb  (Table  I).  3  spontaneous  and  19  MuLV-induced  B10.A  B  cell 
lymphomas  expressed  both  I-A  k and  I-E  k antigens.  In  addition,  in  these  22 
tumors, no serological aberrations were observed in their reaction with any of 
the  11  I-A/E-specific mAb (data not shown). 
However, two primary B10.A B cell lymphomas were observed that displayed 
strong I-E  k but only minimal I-A  k expression at the tumor cell surface (Table II). 
Tumor  1464  arose  spontaneously  and  tumor  1189  was  induced  by  a  milk- 
transmitted B-ecotropic MuLV (6) (Table II). Both tumors had a T200 +, B220  +, 
slg  t/+, Thy-l-, mac-l- phenotype (Table II). Strikingly, both primary I-A-, I-E  + 
tumors were localized exclusively in the greatly enlarged mesenteric lymph node. 
Stability of I-A-,  I-E  + Tumor Phenotype upon  Transplantation.  Both B10.A  I- 
A-, I-E  + tumors were transplanted into several syngeneic recipient mice, which 
developed lymphomas in 4-8 wk (Table III). The transplanted I-A-, I-E  + tumors 
were much more aggressive than the primary I-A-, I-E  + tumors, as indicated by 
extensive tumor cell infiltrations into spleen, mesenteric and other lymph nodes, 
kidney, and  liver.  Tumor  cells from different organs of individual  transplants 
strongly expressed  I-E  k,  as  determined by their reaction  with  the  mAb  13-18 ZIJLSTRA ET  AL.  1217 
TABLE  III 
Relationship Between Transplantability of  Primary B IO.A B Cell Lymphomas and I-AlE 
Expression of  Primary and Transplanted Tumors 
I-A/E phe- 
notype of  Animals with tu-  I-A/E phe-  Transplants 
Tumor  primary  mor after trans-  Latency (d)  notype of 
tumor  plantation*  transplants  tested (n) 
Spontaneous tumors 
1252  I-A<+)E  (+)*  0/3  > 100 
1265  NT  g  0/3  > 100 
1285  NT  4/5  50.2 ±  10.2 I 
1359  I-A<+)E  ~+)  0/6  > 100 
1464  I-A-E  +  4/6  55.2 ±  5.7 
Milk-transmitted MuLV-induced tumors 
I-A+E  +  2 
I-A-E  +  4 
1096  NT  1/9  61  I-A+E  +  1 
1099  I-A(~E  I~  9/9  19.6 ±  1.4  I-A~+)E  (+)  2 
1224  I-A+E  ÷  1/10  96  I-A+E  +  1 
1189  I-A-E  +  2/2  36,40  I-A-E  +  2 
* Transplantation was  performed  by i.p.  inoculation of 5-20  x  l0  n live primary tumor  cells in 
syngeneic recipients. 
* +,  strong expression  (positive cells >50  channels above  background  fluorescence  with  FITC- 
labelled goat anti-mouse Ig); (+), weak expression (positive cells 10-50 channels above background 
fluorescence); -, no expression (positive cells <10 channels above background fluorescence). 
0 NT, not tested because no more live cells were available. 
I Mean __- SD. 
0  100 
control  K  k 
I.A  k  I-E  k 
200  0  100  200 
channel number 
FIGURE  1.  Expression of H-2 antigens by transplant 2 of B10.A tumor 1464 as determined 
by flow cytofluorometry with mAb directed against I-A  k (17/227R7), I-E  k (13-18), and K* (11- 
4.1) antigens. The primary I-A-, I-E  + B 10.A tumors 1464 and 1189, and individual transplants 
of these tumors showed similar fluorescence patterns (data not shown). 
(Fig.  1) and  14-4-4S (data not shown). With mAb  17/227R7  (Fig.  1) and three 
other  I-Ak-reactive  mAb  (data  not  shown),  only  minimal  fluorescence  above 
background was seen. With seven mAb that do not react with I-A  k but detect I- 
A  molecules  from  a  wide  spectrum  of H-2  alleles  (Table  I),  no  reaction  was 
observed. Comparable results were obtained with the primary tumor  1464 and 
the primary and individual  transplants of tumor  1189 (Tables II and III). Both 
the  primary  (data  not  shown)  and  transplanted  (Fig.  1)  I-A-,  I-E  +  tumors 
expressed the  K k molecule on the cell surface (Fig.  1). These findings  make it 
unlikely  that  the  minimal  cell  surface  detection of I-A  k antigens  is  caused by 
either (a) a mix-up of tumor cells, or (b) a mutation in the I-A  k molecule. 1218  IMBALANCED  I-A/E  EXPRESSION  ON  MURINE  B  CELL  TUMORS 
Relationship  between Transplantability  of Primary BIO.A B Cell Lymphomas and 
I-AlE Expression of  Primary and Transplanted  Tumors.  To evaluate the biological 
significance of the  I-A-,  I-E  + phenotype,  we determined  the  I-A/E phenotype 
and  transplantability  of a  total  of nine  B10.A  primary  B  cell  tumors,  namely 
seven random  B10.A B cell tumors and the two I-A-,  I-E  + tumors (Table III). 
Four of these primary  tumors expressed both I-A and  I-E antigens,  while the 
other three were not characterized because no viable primary cells were available. 
Two  out  of  three  of  these  primary  tumors  most  likely  had  an  I-A +,  I-E  + 
phenotype,  however,  because (a)  they were transplantable  and the  transplants 
had an I-A +, I-E  + phenotype (Table III); and (b) all other transplantable  tumors 
also retained the I-A  +, I-E  + phenotype of the primary tumor (Table III). Of the 
seven random B10.A B cell tumors, two were readily transplantable,  two trans- 
plantable in only a small minority of recipient mice, and three not transplantable 
in the number of animals tested (Table III). This frequency of takes is comparable 
to that  of I-A  + B10 B cell tumors (three  out of eight transplantable;  data not 
shown), but differs significantly from the uniformly excellent transplantability of 
the T  cell tumors from the same experimental  model (6,  7),  i.e. all  13  B10.A, 
and all 4 B10 T  cell tumors were readily transplantable (data not shown). 
Expression of Class II MHC-spec~c mRNA in I-A-, I-E  + Tumors.  To further 
document the minimal cell surface I-A expression of the two I-A-, I-E  + tumors, 
and to explore its mechanism(s),  we examined the expression of class II MHC- 
specific mRNA.  The  results of Northern  blot analysis with total cellular  RNA 
are shown in  Fig.  2.  Two individual  transplants  of tumor  1189 (lanes 2 and  3) 
possess a  greatly  reduced  expression  of the  1.4  kb AO mRNA (Fig.  2),  but a 
strong expression of both the A~ (Fig. 2, lanes 2 and 3), E~ (Fig. 2, lanes 2 and 
3), and Ea mRNA (data not shown). Three individual transplants of tumor 1464 
(Fig. 2, lanes 4-6) express a low level of the  1.4 kb Aa mRNA (Fig. 2, lanes 4- 
6) but high levels of AI3 (Fig. 2, lanes 4-6), E~ (Fig. 2, lanes 4-6) and Ea mRNA 
(data not shown). 3 primary B10.A B cell lymphomas (Fig.  2, lanes 7-9) and  11 
other primary or transplanted  B cell lymphomas (data not shown) with a normal 
I-A  +, I-E  + cell surface expression show a comparably high level of expression of 
the  Aa,  A/3, and  E/3  mRNAs.  Comparable  results  were  obtained  in  dot-blot 
analyses (data not shown). 
DNA Analysis of I-A-, I-E  + Tumors.  In Southern  blot analyses with Eco RI-, 
Kpn 1-, Eco RV-, and Hind III-digested DNA, no additional restriction enzyme 
fragments hybridizing with the Aa and Al3 probes are observed in the DNA of 
the two I-A-,  I-E  + tumors,  in comparison  with control  tissues.  In addition,  no 
hybridizing fragments are lost by any of the I-A-, I-E  + B10.A B cell tumors (data 
not  shown).  Southern  blot analyses  with  the  MuLV-specific AKV-LTR probe 
reveal that the DNA of both the MuLV-induced tumor 1189 and the spontaneous 
tumor  1464  contains  a  considerable  number  of integrated  MuLV  proviruses. 
DNA  of individual  transplants  of these  tumors  contains  an  almost  identical 
pattern of MuLV integrations  in comparison with the primary tumor (data not 
shown). 
Chromosome Analyses.  To address the question  whether  the  I-A-,  I-E  + phe- 
notype could be correlated with specific chromosomal aberration(s), chromosome ZI.|LSTRA  ET  AL.  1219 
FIGURE 2.  Expression of class II MHC-specific mRNA by B I0.A B cell lymphomas. North- 
ern blot analysis of 20 #g total cellular RNA on formaldehyde-treated 1.0% agarose gels was 
performed as described (27).  Nitrocellulose filters were successively incubated with the A¢/, 
Aa, and EB specific hybridization probes, washed, and exposed to x-ray film. RNA was isolated 
from: lane  1,  YAC,  T  cell line; lanes 2  and 3,  two individual transplants of the I-A-,  I-E  + 
B10.A tumor  1189; lanes 4-6,  three individual transplants of the I-A-,  I-E  + BI0.A tumor 
1464; lanes 7-9, three individual primary B10.A B cell tumors with I-A  +, I-E  + phenotype. 
spreads of I-A-,  I-E  + transplants  of both tumors were examined by the Giemsa 
banding technique. 
Transplant of Tumor 1189.  A total of 48 metaphases were analyzed, 37 from 
the spleen and  11  from the liver.  All  27  cells with an  XY constitution  had an 
apparently  normal  male  karyotype  and  were  therefore  considered  as  being 
derived from dividing host cells. Cells with an XX constitution represented the 
tumor  cell  population.  The  stem  line  consisted  of the  following  karyotype: 
39,XX,t(4; 19), t(11 ;17), der(18)t(15; 18), -12, +mar 15 (Fig. 3). The breakpoints 
for  the  translocations  were  as  follows:  t(4;19)(E2;B),  t(ll;17)(E2;D),  and 
der(18)t(15;18)(A2;E3).  The  marker  chromosome  15  had  an  insertion  of un- 
known chromosome material in band A2. 
Transplant of Tumor 1464.  A total of 63 metaphases were examined, 35 from 
the spleen and 28 from a lymph node, all of which had an XX constitution and 
were therefore of tumor cell origin.  The numerical  range varied between 48 to 
49 chromosomes per cell.  31  cells were karyotyped; all had +2,  +3,  +16,  +17, 
+ 18, + 19, and a  translocation  t(6; 11)(D;A5). The majority of cells also had an 
extra  chromosome  15  as  a  simple  trisomy,  with  four  instances  of a  tandem 1220  IMBALANCED  I-A/E  EXPRESSION  ON  MURINE  B  CELL  TUMORS 
FIGURE 3.  Representative Giemsa-banded karyotype of a transplant of the I-A-, I-E  + tumor 
1189 showing 39,XX,t(4; 19)(E2;B),  t( 11; 17)(E2;D),  der( 18)t(15; 18)(A2; E3), -  12, +mar 15. 
duplication. An additional number 18 was also present in 10 cells, and nearly all 
metaphases had one or two small unidentifiable marker chromosomes. 
Discussion 
The minimal I-A  k expression on the cell surface of  two B 10.A B cell lymphomas 
is most likely caused by a  strongly reduced level of Aa- (tumor  1464)  or At$- 
(tumor 1189) specific mRNA. We cannot exclude that some of the residual signal 
of Aa or Ai3 mRNA is caused by cross hybridization of the hybridization probes ZIJLSTRA ET  AL.  1221 
used.  Several  mechanisms  could account  for  these  imbalances  in  Aa  and  A3 
mRNA expression. 
First, soluble mediators (e.g., interferons, growth factors) may induce mRNA 
expression and  cell surface expression  of the  I-A or  I-E molecules selectively. 
This hypothesis is supported by the observation that, on human endothelial cells 
and dermal fibroblasts, recombinant  human  IFN-~/enhances the expression of 
HLA-DR more  strongly  than  of HLA-DC  antigens  (48).  In  addition,  in  the 
human  myelocytic  leukemia  cell  line  HL-60,  IFN-~  induces  the  cell  surface 
expression of DR but not of DC antigens (49).  The induction  by IFN-~/of DR 
antigens on HL-60 cells is associated with the induction of high  level DRa and 
DR3 mRNA, without a simultaneous induction of DCa and DC3 mRNA expres- 
sion (49).  In organs of moribund mice, which almost exclusively contain malig- 
nant B cells, the relative scarcity of (T cell-dependent) mediators could account 
for the absence of I-A expression. In pilot experiments, however, we were unable 
to induce I-A  k expression in an in vitro cell line of the I-A-, I-E  + tumor 1464 by 
in vitro administration  of recombinant mouse IFN-y (data not shown). 
Second,  the  I-A-  tumors  may  contain  altered  promoter  and/or  enhancer 
regions of the A0t  (tumor  1464)  or A3 gene  (tumor  1189).  Subtle nucleotide 
changes or small insertions/deletions in the Ao~ or A3 genes may not be detected 
by the Southern blot analyses performed in this study. The existence of separate 
enhancer elements for class II MHC genes may be indicated by the differential 
tissue distribution  and  ontogeny of DC-I  and  HLA-DR antigens  in  man  (50). 
Moreover,  recently,  a  cell  type-specific enhancer  element  associated with  the 
mouse E3 gene has been identified (51). Alteration of (a) transcriptional  control 
site(s) may be related to the chromosomal aberrations involving chromosome 17 
(trisomy  or  translocations)  observed  in  both  I-A-  tumors,  and  may  thereby 
influence the relative mRNA expression of the I-A and I-E genes. In this respect 
it is striking  that one of the I-A-, I-E  + tumors contains a  (11;  17) translocation 
with a breakpoint on chromosome 17 that is localized within or very close to the 
H-2 complex, which has been assigned to the  17C-E1  region of chromosome 17 
(52). Although we have found no confirmation that this breakpoint maps within 
the I-A region itself, a  region close to I-A could be involved. Otherwise,  this I- 
A-, I-E  + tumor still  possesses a cytogenetically normal chromosome  17. Hence, 
the (11;  17) translocation may represent an event independent from the loss of 
I-A  k expression, but associated with the induction of the malignant state of mouse 
B cell lymphomas with a  less differentiated phenotype than murine plasmacyto- 
mas, which often contain a  (12;  15) or (6;  15) translocation  (53, 54). So far we 
have  examined  the  karyotype of two additional  B10.A  B  cell  tumors  (which 
possess an I-A  +, I-E  + phenotype).  In the karyotype of a transplant  of the I-A  (+~, 
I-E  (+~ tumor  1099  (Table  III),  trisomy  of the  chromosomes  11  and  15  was 
observed (data not shown). In a transplant  of the I-A  +, I-E  + B10.A tumor  1285 
(Table III), a large number of chromosomal aberrations was present,  including 
a  t(3;9)(D;D) and  two chromosomes  11  containing  insertion  of unknown chro- 
mosomal  material  (data  not  shown).  Hence,  in  conclusion,  the  chromosomal 
aberrations  present  in  the  B10.A  B  cell  lymphomas  investigated  thus  far  are 
rather  heterogeneous.  However,  in  all  four  B10.A  B  cell  tumors  examined, 
abnormalities in chromosomes  11  and  15 were observed, resembling the chro- 1222  IMBALANCED  I-A/E  EXPRESSION  ON  MURINE  B  CELL  TUMORS 
mosomal  aberrations  reported  for  plasmacytomas  induced  by  mineral  oil  in 
combination with the Abelson-Moloney virus (54). This raises the possibility that 
in  tumor  1189,  as  a  result  of the  (11;  17)  translocation,  one  of the  cellular 
oncogenes on chromosome  11 (i.e. p53, erbA, erbB, or others) is brought under 
control of promotor and/or enhancer regions present within the H-2 complex. 
Third,  the B10.A B cell lymphomas may contain unaltered Aa and AI3 genes 
but  express  unknown  tumor  cell-associated  cellular  proteins  that  modify the 
level of Aa or AI3 mRNA. These unknown proteins could influence transcription 
of the Aa or AI3 gene through  direct regulation of the activity of the promoter 
or enhancer  regions of the  genes involved. Alternatively,  these proteins could 
influence the stability of Aa or A/3 mRNA. A direct role of a  MuLV protein, in 
analogy with the adenovirus  12 E1A product (27, 28), seems unlikely, because a 
large  number  of  MuLV-expressing  murine  B  cell  lymphomas  show  normal 
expression  of I-A/E  mRNA  and  antigens.  However, the  generation  of a  mu- 
tant/recombinant MuLV that encodes such a protein cannot be excluded. 
Two murine B cell tumors were observed with strongly reduced cell surface I- 
A  expression.  Noteworthy, in another study,  3 out of 20 B cell non-Hodgkin's 
lymphomas in man were also shown to lack expression of DC antigens (the human 
analog of the mouse I-A antigen  [55]), in spite of a  high expression of DR and 
SB  gene  products  (56).  Perhaps  an  I-A-,  I-E  +  phenotype  may  be  a  normal 
phenomenon at some stage in the differentiation of mouse B cells, although  to 
our knowledge such a population of B cells has not yet been reported. However, 
the  observation  that  in  one  tumor  a  reduced  Aa  mRNA  but  in  the  other  a 
reduced A/~ mRNA level was observed argues against this hypothesis.  A  more 
likely explanation  for the minimal expression or lack of I-A antigen is immuno- 
selection to  escape  from  I-A-restricted  immune  surveillance  in  vivo.  The  fre- 
quency of aberrant I-A expression in primary B 10.A B cell lymphomas (2 out of 
24) is  low. Although  both  I-A-,  I-E  + tumors were transplantable  in  syngeneic 
mice,  the  overall  transplantability  frequency of B10.A B cell lymphomas does 
not allow any conclusion concerning a difference in transplantability of I-A-,  I- 
E + vs.  I-A  +,  I-E  + tumors,  if only because the  frequency of testable  I-A-,  I-E  + 
tumors is too low. In addition,  no selection towards an I-A-,  I-E  + phenotype is 
apparent  upon  transplantation  of I-A  +,  I-E  +  tumors.  However,  this  does  not 
exclude the possibility that  immunoselection against a  class II  MHC-restricted 
MuLV-specific T  cell response may occur in some of the B cell lymphomas.  In 
other  individual  tumors,  immunoselection  may involve loss of the  viral  target 
antigen  rather than  MHC molecules from the cell surface.  Immunoselection in 
vivo by class I MHC-restricted Moloney MuLV-specific CTL leading to the loss 
of the viral target antigen was recently documented by van der Hoorn et al. (57). 
The ultimate answer of whether the I-A-, I-E  + phenotype of tumors  1189 and 
1464 has biological significance has to come from transfection and expression of 
cloned Aa and Aft genes in these tumors, followed by study of the comparative 
transplantability of transfected vs. untransfected tumor lines. 
Summary 
To study the role of class II MHC expression in mouse lymphomagenesis, we 
examined  the  cell surface expression  of I-A/E antigens  on  24 spontaneous  or ZIJLSTRA ET  AL.  1223 
murine leukemia virus (MuLV)-induced mouse B10.A (I-A  k, I-E  k) B cell lympho- 
mas.  Two  primary  B10.A  B  cell  lymphomas  were  observed  with  strong  I-E  k 
expression but with only minimal cell surface I-A  k expression.  Both tumors are 
readily  transplantable  in syngeneic  mice,  with  maintenance  of their I-A-,  I-E  + 
phenotype.  Strikingly,  one  I-A-,  I-E  +  B  cell  lymphoma  contains  a  (11;  17) 
translocation  with a  breakpoint  on chromosome  17  that  is localized  within  or 
very close to the H-2 complex. DNA of both tumors contains normal restriction 
enzyme fragments of the Aa and A/3 genes. Northern blot analyses indicated that 
one I-A-, I-E  + tumor strongly expressed Ao~, Ea, and EB mRNAs but possessed 
only a weak expression of AI3 mRNA. The other B cell  lymphoma showed AB, 
Ea, and E/~ mRNA expression but only minimal  Aa mRNA expression.  In  11 
primary  B10.A  B  cell  lymphomas  with  a  normal  I-A  +,  I-E  +  phenotype,  no 
imbalances  in Aa/AB mRNA  levels  were  observed.  The  implications  of these 
findings  for  the  role  of class  II  MHC  expression  in  mouse B  cell  lymphoma- 
genesis are discussed. 
We  thank  Dr.  R.  N.  Germain  for providing the  class  II MHC-specific hybridization 
probes, Dr. G.J. H~immerling for providing the I-A/E-specific mAb, Dr. T. Radaskiewicz 
for the morphological characterization of the tumor cells,  Dr. G. Levan (Department of 
Genetics, University of G6teborg) for his assistance in the chromosomal analysis, and our 
colleagues for helpful discussions. 
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